Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Home
Harm van Tinteren

Harm van Tinteren

Head Trial and Data Center

Trial and Data Center

Phone 31 65 01 73 064

Email H.vanTinteren@prinsesmaximacentrum.nl

Pediatric renal tumor epidemiology
- jan. 2023
- Jaime, Libes, et al
- Pediatric Blood and Cancer
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer
- nov. 2022
- Sonja B., Vliek, et al
- European Journal of Cancer
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
- jul. 2022
- M., Opdam, et al
- Breast Cancer Research and Treatment
International Comparisons of Clinical Demographics and Outcomes in the International Society of Pediatric Oncology Wilms Tumor 2001 Trial and Study
- mei 2022
- Joaquim Caetano, De Aguirre-Neto, et al
- JCO Global Oncology
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
- apr. 2022
- Linde, Dekker, et al
- Blood advances

View all publications

Harm van Tinteren

Publications

Pediatric renal tumor epidemiology

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

International Comparisons of Clinical Demographics and Outcomes in the International Society of Pediatric Oncology Wilms Tumor 2001 Trial and Study

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia